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Background: Carotid plaque echolucency as detected by Color Doppler ultrasonography (CDUS) has been used as
a potential marker of plaque vulnerability. However, contrast-enhanced ultrasound (CEUS) has recently been shown
to be a valuable method to evaluate the vulnerability and neovascularization within carotid atherosclerotic plaques.
The aim of this study was to compare CEUS and CDUS in the assessment of plaque vulnerability using transcranial
color Doppler (TCD) monitoring of microembolic signals (MES) as a reference technique.
Methods: A total of 46 subjects with arterial stenosis (≥ 50%) underwent a carotid duplex ultrasound, TCD
monitoring of MES and CEUS (SonoVue doses of 2.0 mL) within a span of 3 days. The agreement between the
CEUS, CDUS, and MES findings was assessed with a chi-square test. A p-value less than 0.05 was considered
statistically significant.
Results: Neovascularization was observed in 30 lesions (44.4%). The vascular risk factors for stroke were similar and
there were no age or gender differences between the 2 groups. Using CEUS, MES were identified in 2 patients
(12.5%) within class 1 (non-neovascularization) as opposed to 15 patients (50.0%) within class 2 (neovascularization)
(p = 0.023). CDUS revealed no significant differences in the appearance of the MES between the 2 groups
(hyperechoic and hypoechoic) (p = 0.237).
Conclusion: This study provides preliminary evidence to suggest that intraplaque neovascularization detected by
CEUS is associated with the presence of MESs, where as plaque echogenicity on traditional CDUS does not. These
findings argue that CEUS may better identify high-risk plaques.
Keywords: Contrast-enhanced ultrasound (CEUS), Plaque vulnerability, Monitoring of microembolic signals (MES),
Color Doppler ultrasonography (CDUS)Background
Internal carotid artery (ICA) disease is frequently observed
in ischemic stroke patients. Histological and imaging
studies [1-3] have demonstrated that stroke is dependent
on the degree of stenosis and the morphological features
of the plaque, such as ulcers or fissures. These morpho-
logical features can cause a rupture [4] of the plaque and* Correspondence: yyangyangzhou@gmail.com
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reproduction in any medium, provided the orresult in embolization, which is known as “vulnerability”.
All of these factors should be considered when developing
an accurate diagnostic and preventive approach aimed at
risk stratification and treatment planning to reduce the
incidence and severity of acute cerebrovascular disease.
Color Doppler ultrasonography (CDUS) has been the the
screening test of choice for assessing carotid atheroscler-
osis. Echolucency of the Carotid plaque is a valuable
marker of the plaque vulnerability [5-7].
However, recently several studies have confirmed the
feasibility of using contrast-enhanced ultrasound (CEUS)
for the evaluation of neovascularization within carotidtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 2 Differences in the clinical characteristics of group







Age (years), mean ± SD 62.22 ± 6.31 62.96 ± 9.54 0.456
Men, n (%) 26 (92.9%) 17 (94.4%) 1.000
Neurological symptoms*, n (%) 16 (57.1%) 8 (44.4%) 0.295
Hypertension, n (%) 17 (60.7%) 10 (55.6%) 0.767
Diabetes mellitus, n (%) 8 (28.5%) 5 (27.8%) 1.000
Hypercholesterolemia, n (%) 15 (53.6%) 12 (66.7%) 0.541
Current smoker, n (%) 18 (64.3%) 13 (72.2%) 0.749
*Neurological symptoms include previous transient ischemic attacks (TIA),
dysphasia, single limb paresis, and amaurosis fugax.
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may also be used to assess the vulnerability of carotid
plaques [8-11]. Levovist is an ultrasound contrast agent
(BR1; Bracco SpA, Milan, Italy; Definity, Lantheus Med-
ical Imaging) that enables the optimization of technically
difficult explorations using a Doppler signal of sufficient
intensity and improves the detection of minimal flow
rates and slow velocities in severe cases of stenosis.
Previous studies [12,13] demonstrate that echolucent
plaques tend to have greater contrast enhancement com-
pared to echogenic plaques. Echolucent plaques are
known to exhibit a larger number of vulnerable patho-
logical features and correlate with a higher risk of cere-
brovascular events [14]. However, studies to determine
the most accurate technique for assessing plaque vulner-
ability have been limited. The aim of our study was to
compare CEUS-detected neovascularization with plaque
morphology on CDUS with regards to their correlation
with MESs.
Materials and methods
Patient group and informed consent
This study was approved by the local ethics committee
and written informed consent was obtained from all
patients. The following data was recorded from the pa-
tient: age, sex, previous symptoms (Transient ischemic
attacks (TIA), dysphasia, single limb paresis and amaur-
osis fugax) and co-morbid risk factors (hypertension,
hyperlipidemia, diabetes and smoking habits) (Table 1
and Table 2). Both asymptomatic and symptomatic
patients were included.
Between March 2011 and March 2012, 54 sub-
jects with arterial stenosis (≥50%) underwent CDUS
(PSVICA≥125 cm/s and visible plaque [15]) at the First
Norman Bethune Hospital of Jilin University. In addition,
TCD monitoring of MES and CEUS examinations were
performed within 3 days by two independent researchers
(Y.L. and Y.B.). MES monitoring was performed by twoTable 1 Differences in the clinical characteristics of class
1 (non-neovascularization) and class 2






Age (years), mean ± SD 64.38 ± 11.32 61.50 ± 6.26 0.186
Men, n (%) 16 (100%) 27 (90%) 0.542
Neurological symptoms*, n (%) 6 (37.5%) 18 (60%) 0.217
Hypertension, n (%) 9 (56.3%) 13 (43.3%) 0.538
Diabetes mellitus, n (%) 3 (18.8%) 9 (30.0%) 0.498
Hypercholesterolemia, n (%) 9 (56.3%) 18 (60.0%) 1.000
Current smoker, n (%) 8 (50.5%) 19 (63.3%) 0.531
*Neurological symptoms include previous transient ischemic attacks (TIA),
dysphasia, single limb paresis, and amaurosis fugax.neuroradiologists (Y-Q.X and Y.C.). Patients with any of
the following conditions were excluded: [1] complete ICA
occlusion or <50% stenosis based on CDUS; [2] evidence
of cardioembolism, such as atrial fibrillation, mechanical
valve replacement, left atrial or left ventricular thrombus,
bacterial endocarditis, or recent myocardial infarction; [3]
ipsilateral stenosis of the middle cerebral artery (MCA) or
intracranial internal carotid artery in the TCD; [4] a poor
temporal window; or [5] poor image quality of the vessel
wall or lumen. Therefore, data from remaining 46 patients
(43 male and 3 women) with satisfactory image quality
were analyzed.
Color Doppler ultrasonography (CDUS)
We used an ultrasound Philips iU22 system (Philips
Healthcare Solutions, Bothell, WA, USA) equipped with
an L-9-3 linear-array transducer. The instrument was
operated by 2 experienced readers (Y-YZ and YC), who
were blinded to all of the clinical laboratory findings and
other imaging data.
The maximal thickness of the lesion located at the
bifurcation and proximal to the bifurcation was assessed
as a continuous variable and measured from the anterior,
lateral and cross-sectional scanning plane using a longi-
tudinal image from the media-adventitia to the intima-
lumen boundaries. The B-mode settings were adjusted
to optimize the quality of the gray-scale images and the
pulse repetition frequency (PRF) used with the color
Doppler flow imaging was adjusted according to the flow
velocity.
The characteristics of the plaques were described
according to the modified Gray Weale classification [16].
The lesion echogenicity was classified into group 1 (uni-
formly hyperechoic or predominantly (>50%) hyperechoic)
or group 2 (uniformly hypoechoic or predominantly
(>50%) hypoechoic). All results were agreed upon by at
least two experienced neuroradiologists.
Table 3 Comparison of the MES measurements (mean D)
of class 1 (non-neovascularization) and class 2
(neovascularization) determined by CEUS
Class 1 (n = 16) Class 2 (n = 30) P-value
MES (z), n (%) 2 (12.5) 15 (50.0) 0.023
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A contrast-enhanced ultrasound examination was per-
formed using an Acuson Sequoia 512 imaging system
(Siemens, Mountain View, CA, USA) with a 2-MHz
transducer by 2 experienced readers (Y.B. and Y.L.), who
were blinded to all of the clinical laboratory findings and
other imaging data. Disagreements between the readers
were settled by a consensus reading. The patients were
placed in a supine position. A 5-mL solution was pre-
pared from 1 mL of the activated contrast agent (BR1;
Bracco SpA, Milan, Italy; Definity, Lantheus Medical
Imaging) diluted in 4 mL of saline. An initial bolus injec-
tion was quickly performed. The second injection was
performed slowly and was followed by 5 mL of normal
saline to flush out the contrast from the vein. The time
gap between the injections was approximately 3 minutes.
The contrast-enhanced ultrasound imaging application
included a low mechanical index (0.07) to avoid early
bubble destruction and harmonics with pulse inversion
to optimize the depiction of the IV contrast agent and
minimize echoes from the surrounding tissues. Cine
loops were recorded for 5 heart cycles, starting from the
time in which the contrast agent could be observed in
the carotid lumen. Following the infusion of the ultra-
sound contrast agent, the lumen of the carotid artery
was enhanced, resulting in visualization of enhanced
plaque luminal morphology. The presence of blood flow
“activity” was identified on the basis of the dynamic
movement of the echogenic reflectors (microspheres) in
the intraplaque microvessels.
Intraplaque neovascularization (contrast agent enhance-
ment) was categorized using a modified grading scale and
classified as class 1 (non-neovascularization) or class 2
(neovascularization).
TCD ultrasound examination
MES monitoring was performed by two experienced
neuroradiologists (Y-YZ and YC) with a TCD machine
(EME TC8080; Nicolet, Madison, WI, USA) with a 2-
MHz transducer. The patients were placed in the supine
position and bilateral MCA recordings were obtained for
30 minutes at a depth of 44–60 mm. The MES were
identified on the basis of Doppler waves obtained from
the MCA ipsilateral to the side of the ICA stenosis. The
following definitions for emboli signals were used: typ-
ical, visible, and audible (click, chirp, whistle). Short-
duration, high-intensity signals within the Doppler flow
spectrum occurred at random intervals during the
cardiac cycle. Signals were defined at 6 dB above the
background threshold on the basis of standard consen-
sus criteria described in previous studies. The presence
of MES was assessed by an independent expert reader
(Y-QX), who was blinded to all of the clinical laboratory
findings and other imaging data.Database and statistical analysis
All of the data were analyzed with SPSS 17.0. The results
are expressed as the mean value and standard deviation
(SD) for each measurement. Categorical variables were
assessed using the chi-square test. A p-value of less than
0.05 was considered statistically significant.
Results
Forty-six patients (43 men and 3 women) with satisfac-
tory image quality were analyzed. The differences in the
clinical characteristics are reported in Table 1 and
Table 2.
CEUS revealed neovascularization in 30 patients (44.4%).
The stroke vascular risk factors were similar between
groups, and there were no age or gender differences be-
tween the 2 classes (Table 1). MES were observed in 2 pa-
tients (12.5%) within class 1 (non-neovascularization) and
in 15 patients (50.0%) within class 2 (neovascularization)
(p = 0.0230) (Table 3, Figure 1).
Using CDUS, 28 patients were identified in group 1
(hyperechoic), and 18 were identified in group 2
(hypoechoic). Stroke vascular risk factors, age and gender
were similar between the 2 groups (Table 2). Moreover, no
significant differences were observed in the appearance of
the MES between the 2 groups (p = 0.2368) (Table 4).
Discussion
In this study, we examined the relationship between CEUS
and CDUS characteristics of the carotid plaque with
special reference to MES. We found an association be-
tween MES monitoring and the degree of contrast-agent
enhancement using ultrasound imaging (p=0.0230). How-
ever, we did not observe a significant association between
the MES results and CDUS properties (p = 0.2368).
Although plaque echolucency is a marker of high-risk
lesions (rupture prone plaques), our findings indicate that
CEUS appears to be more accurate at assessing plaque
vulnerability.
CDUS has replaced digital subtraction angiograph for
the diagnosis of carotid stenosis, in part because CDUS
provides enhanced definition of plaque morphology
[17,18]. Several studies [5,14,19-21] have demonstrated
that echogenic plaques are well-established markers of
high-risk lesions and are associated with the presence of
neurological symptoms and the development of future
strokes in previously symptomatic individuals. Further-
more, echogenic plaques also coincide with the occur-
rence of acute coronary syndromes. Several studies have
Figure 1 A 56 year-old female patient with TIA. CEUS (A and B) detected 2 consecutive frames of intra-plaque neovascularization (yellow arrow).
MES (red arrow) was detected in the ipsilateral middle cerebral artery (C and D).
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rupture due to their increased lipid content and macro-
phage density as well as intraplaque hemorrhage; in
addition, increased plasma and low-density lipoprotein
cholesterol levels make them vulnerable and prone to
ulceration and embolization.
Neovascularization is considered an important feature
in plaque development and vulnerability and is triggered
by inflammation and hemorrhage [8,27,28]. The vulner-
ability of the neovasculature to rupture increases the risk
of cerebral emboli. Several pathological studies [28-30]
have confirmed that plaque rupture is strongly associ-
ated with the presence and degree of neovascularization
within the plaque.
Intraplaque microvessels (angiogenesis) within the
atherosclerotic lesions arise mainly from the adventitial
vasa vasorum. Extension of the vasa vasorum to the full
thickness of the media and intima of atherosclerotic
segments represents pathological neovascularization,
which is stimulated by plaque hypoxia, reactive oxygen
species, hypoxia-inducible factor signaling and inflam-
mation [31,32].
Feinstein et al. [33] and Assaf Hoogi et al. [11] com-
pared the results of CEUS with histological characteris-
tics. Their findings revealed that contrast enhancementTable 4 Comparison of the MES measurements (mean D)
of group 1 (hyperechoic) and group 2 (hypoechoic)
determined by CDUS
Group 1(n = 28) Group 2 (n = 18) P-value
MES (z), n (%) 12 (42.9) 5 (27.8) 0.237within the plaque is correlated with a higher number of
microvessels. The studies of Staub et al. [10] and
Faggioli et al. [34] have indicated the feasibility of using
CEUS to depict neovascularization within the carotid
plaque to facilitate the further stratification of the risk of
rupture of carotid artery lesions. Thus, CEUS has been
proposed as a method to preoperatively identify vulner-
able plaques.
Consistent with the data obtained in previous reports
[12,13], neovascularization visualized using CEUS is cor-
related with the morphological features of plaque vulner-
ability, including echogenic plaques, as a marker of high
risk lesions.
Coli et al. [12] reported that carotid plaque contrast
agent enhancement correlated with echogenic plaques
(p = 0.001) and is associated with the histological density
of neovessels. Interestingly, intraplaque neovascularization
in CEUS images correlated well with histological
microvessel density rather than plaque echolucency
suggesting that low echo intensity is not correlated with
the histological density of the vasa vasorum. Thus CEUS
is a more specific imaging modality to identify highly
vascularized and inflamed vulnerable lesions as compared
to standard CDUS in isolation.
Our observations strongly indicate a positive relation-
ship between neovascularization in plaques and MES
while there is a poor correlation between plaque
echolucency and MES. Embolism is an important mech-
anism of cerebral infarcts in patients with ICA stenosis
[35]. The detection of cerebral microembolisms by trans-
cranial Doppler sonography may permit the definition of a
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high-grade internal carotid artery stenosis [36]. To the
best of our knowledge, this is the first study to explore
neovascularization in stroke patients with ICA stenosis
using MES and CEUS.
There were some limitations in this study. The first
limitation was that the pilot study was conducted with a
small sample size. Second, we used a semi-quantitative
approach to evaluate the contrast-agent enhancement;
however, this limitation does not alter our observations
or conclusions. This quantitative method needs to be
further investigated. Finally, several patients could not
be examined because of an inadequate insonation win-
dow during the TCD monitoring that prevented further
analysis. Future studies in larger populations are
required to validate the results of the present study.
Moreover, prospective clinical studies are also needed to
evaluate the use of contrast-enhanced ultrasound
imaging of plaque neovascularization to assess the risk
of cerebrovascular events and to monitor the effects of
anti-atherosclerotic therapies.Conclusions
Intraplaque neovascularization detected by CEUS but not
plaque echolucency is correlated with MES, suggesting
that CEUS may provide valuable information about plaque
risk stratification and may be an accurate method for
assessing vulnerable plaques beyond the echogenicity of
CDUS.
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